- Clinical Trials
Genprex’s common stock is listed on the Nasdaq Capital Market under the symbol “GNPX”.
The Company’s initial public offering of its common stock on the Nasdaq Capital Market occurred on March 29, 2018. The price was: $5 per share.
Genprex is headquartered in Austin, Texas.
Genprex was founded in April 2009.
Genprex is incorporated under the laws of the State of Delaware.
You can view our management team by visiting our website.
Genprex’s fiscal year end is December 31.
For Genprex’s common shares listed on the Nasdaq Capital Market, the CUSIP number is 372446 104.
Shares can be purchased through a stockbroker of your choice.
Currently, Genprex does not pay dividends.
Currently, Genprex does not have a direct stock purchase plan.
Genprex’s auditor is Dazskal Bolton LLP.
V Stock Transfer, LLC
18 Lafayette Place
Woodmere, NY 11598
Ph: (212) 828-8436
Email: [email protected]
Please contact our transfer agent, V Stock Transfer, LLC, through their website or by phone at (212) 828-8436. The company can look up your records and make any necessary adjustments. There is a fee involved for replacing lost certificates.
You must send both your old and new addresses to our transfer agent, V Stock Transfer, LLC, by U.S. mail. Each stockholder in question must sign the request for an address change.
Genprex’s legal counsel is Streusand, Landon & Ozburn LLP.
You can view information on our platform and programs by visiting the Technology section of our website.
You can view our recent press releases by visiting the Media section of our website.
Quarterly & Annual Reports and other investor materials are available under SEC Filings of the Investors & Media section of our corporate website. Additionally, all SEC filings can also be accessed directly from the SEC at www.sec.gov.
More information can be found on the Genprex website and the SEC website.
GNPX Investor Relations
(877) 774-GNPX (4679) ext. #2
We’re passionate about the work we’re doing to fight cancer and diabetes, and we want to keep our current and potential investors informed on our day-to-day advancements. For up-to-the-minute company news delivered straight to your inbox, sign up for our email newsletter.